Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Health
Vandana Singh

Why STAAR Surgical's Shares Are Gaining Today

  • The FDA approved STAAR Surgical Company's (NASDAQ:STAA) EVO/EVO+ Visian Implantable Collamer Lens to correct myopia and myopia with astigmatism. Myopia, also known as nearsightedness or the need for distance vision correction.
  • The Company, in a statement, says that the EVO lens is additive, provides quality of vision day & night, does not cause dry eye syndrome, and, if required, can be removed by a doctor. 
  • EVO offers a lens-based alternative for the correction/reduction of refractive error in people who currently use glasses and/or contact lenses for distance vision correction. 
  • A U.S. multicenter, prospective clinical investigation confirmed the safety of the EVO family of myopia lenses. 
  • Read Next: BTIG Upgraded Staar Surgical Stock - Read Why.
  • More than 100 clinical papers are available discussing the safety and efficacy of the Visian ICL family of lenses globally.
  • Price Action: STAA shares are up 9.47% at $79.86 on the last check Monday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.